Thomas L. Petty Aspen Lung Conference 59th Annual Meeting

Thomas L. Petty Aspen Lung Conference 59th Annual Meeting is organized by Pulmonary Sciences and Critical Care Medicine and would be held during Jun 08 - 11, 2016 at The Gant Conference Center, Aspen, Colorado, United States of America. The targeted audience for this medical meeting basically for Physicians.

Objectives of the Thomas L. Petty Aspen Lung Conference :

To provide an international forum for leading clinicians and researchers to exchange ideas regarding fundamental concepts underlying innate responses during all phases of lung transplantation including lung inflammation during preservation injury and implantation, airway immunology, genetics/genomics, pathology, molecular biology and novel monitoring and diagnostic methods.
2.To showcase recent advances in lung transplantation and to explore ongoing challenges in allograft health and survival. The goal is to stimulate interactions and facilitate concept integration between the often siloed scientific fields of clinical lung transplantation, immunology and pathology and ultimately identify and integrate emerging, shared interests such as innate immune dysregulation, fibrosis and regeneration.
3.To move forward the concept of molecular and clinical phenotyping of lung transplant complications including ischemia reperfusion injury or primary graft dysfunction, acute rejection and chronic lung allograft dysfunction to improve the efficiency and success of translating scientific advances into direct patient benefit as well as strategies to better prioritize scientific questions based on clinical needs.
4.To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of transplant pathobiology.
At the conclusion of this conference attendees will be able to:
1) Discuss State-of-the-Art concepts regarding the pathophysiological continuum between lung inflammation, immunology and the heterogeneity of lung allograft dysfunction phenotypes. 2) Appreciate the complex interactions between endothelial and epithelial cells, inflammatory cells and matrix which modulate the processes of lung innate and adaptive immunity in lung allograft rejection.
3) To translate basic concepts and to understand challenges in current clinical trial design, and identify approaches to maximize the efficacy of translation of basic science advances in lung injury and repair.
4) Apply principles of lung transplant injury and regeneration to other inflammatory pulmonary conditions which might similarly benefit by these lines of inquiry.